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Extracellular nucleosides and nucleotides, such as adenosine and adenosine
triphosphate (ATP), are involved in many physiological and pathological processes in
adipose tissue (AT). It is becoming accepted that, in addition to the well-established
sympathetic and hormonal system, purinergic receptors contribute significantly to
regulation of adipocyte functions. Several receptor subtypes for both adenosine (P1)
and ATP (P2X and P2Y) have been characterized in white adipocytes (WA) and brown
adipocytes (BA). The effects mediated by adenosine and ATP on adipocytes are
multiple and often differing, depending on specific receptors activated. Using a variety of
agonists, antagonists and transgenic animals it has been demonstrated that adenosine
and P2 receptors are involved in lipolysis, lipogenesis, adipokines secretion, glucose
uptake, adipogenesis, cell proliferation, inflammation, and other processes. Given their
central role in regulating many AT functions, purinergic receptors are considered
potential therapeutic targets in different pathological conditions, such as obesity and
type-2 diabetes. To achieve this goal, specific and potent P1 and P2 receptors activators
and inhibitors are being developed and show promising results. However, more insight
is needed into the function of P2 receptors in brown and beige adipocytes and their
potential role in thermogenesis. This review aims at summarizing current knowledge on
the patho-/physiological role of P1, P2X, and P2Y receptors in WA and BA and their
potential exploitation for pharmacological intervention. Furthermore, we analyze impact
of purinergic signaling in AT – in health and metabolic diseases.
Keywords: purinergic receptors, adenosine, ATP, adipocytes, obesity, type-2 diabetes, inflammation, adipose
tissue
INTRODUCTION
Metabolic disorders, such as obesity, dyslipidemia, and hyperglycemia, are closely related to
AT dysfunction, and indeed AT is considered one of the most promising therapeutic targets
(Guilherme et al., 2008; Kusminski et al., 2016). AT is a metabolic and endocrine organ consisting
mainly of adipocytes. In addition, AT contains other cell types collectively named SVF, which
Abbreviations: AT, adipose tissue; ADP, adenosine diphosphate; ATP, adenosine triphosphate; BA, brown adipocytes; BAT,
brown adipose tissue; BzATP, 2′-3′-O-(4-benzoylbenzoyl)-ATP; cAMP, cyclic AMP; FFAs, free fatty acids; HFD, high fat
diet; IL-, interleukin; KO, knockout; MSCs, mesenchymal stem cells; PAI-1, plasminogen activator inhibitor-1; PKA, protein
kinase A; PLC, phospholipase C; SVF, stromal vascular fraction; TNFα, tumor necrosis factor-α; UCP1, uncoupling protein-1;
UDP, uridine diphosphate; UTP, uridine triphosphate; VNUT, vesicular nucleotide transporter; WA, white adipocytes; WAT,
white adipose tissue.
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includes MSCs, preadipocytes, endothelial cells, fibroblasts, and a
variety of immune cells such as macrophages and T regulatory
cells. Mammals have two main types of AT: WAT comprises
mainly of WA, which store excess energy as triglycerides;
and BAT, characterized by mitochondria-rich adipocytes, which
express UCP1 that enables dissipation of energy by production
of heat. Within WAT, there are also UCP1-positive cells with
thermogenic capacity called beige or brite (brown-in-white)
adipocytes. Cold exposure or other specific factors can produce
browning of WAT (Harms and Seale, 2013; Kim and Plutzky,
2016). WAT and BAT are innervated by the sympathetic nervous
system that together with hormones and other factors regulates
adipocyte function (Bulloch and Daly, 2014). Adipocytes are
also regulated by nucleosides and nucleotides, such as adenosine
and ATP.
Generally, ATP is released from sympathetic nerves
(Burnstock, 2007) and this is also likely in AT (Gnad et al., 2014),
though only sympathetic nerves innervating BAT were found
to express the ATP transporter VNUT (Razzoli et al., 2016).
Many other non-excitable cells, such as epithelial, glial, stromal,
and immune cells release ATP in basal conditions (Corriden
and Insel, 2010) and in response to various patho-/physiological
stimuli (Junger, 2011; Novak, 2011; Lazarowski, 2012). Similarly,
ATP could be released from adipocytes (Gnad et al., 2014;
Adamson et al., 2015). The mechanism of ATP release is not
extensively studied; so far one study suggests channel pannexin-1
(Adamson et al., 2015) and another vesicular-based mechanism
(Razzoli et al., 2016). Other cells in AT could also release ATP,
contributing to a purinergic cross-talk between different cells, but
such signaling is yet to be explored. In the extracellular space ATP
is hydrolyzed to adenosine by one or more ecto-nucleotidases
belonging to four families: ecto-nucleoside triphosphate
diphosphorylases (CD39 type), ecto-5′-nucleotidase (CD73
type), ecto-nucleotide pyrophosphatase/phosphodiesterases
(NPP) and alkaline phosphatases (APs) (Zimmermann et al.,
2012). Interestingly, one of the enzymes NPP2, also known as
phospholipase D or autotaxin, is multifunctional and released
by adipocytes, and up-regulated autotaxin expression correlates
with obesity (Rancoule et al., 2014). Nevertheless, it is most often
assumed that adipocytes can release adenosine, possibly through
nucleoside transporters (Antonioli et al., 2008; Gnad et al., 2014).
Adenosine, ATP, and other nucleotides signal through
purinergic receptors that operate in virtually all mammalian
cells, and it can be disturbed in various diseases, including
metabolic syndrome, and therefore is attractive for therapeutic
targeting (Burnstock, 2013; Burnstock and Novak, 2013; Chen
et al., 2013; Jacobson and Muller, 2016). Here, we summarize
the current knowledge about (i) the expression and function of
adenosine receptors (P1R) and P2 receptors (P2XR and P2YR)
in white, brown, and possibly in beige adipocytes; (ii) their
role in the onset and progression of metabolic disorders; and
(iii) their potential as therapeutic targets. In some cases, it is
difficult to dissect the contribution of purinergic signaling in
adipocytes from the AT/whole body effects (Peleli and Carlstrom,
2017). This is because the SVF in AT and other organs express
purinergic receptors, and various conditions (e.g., inflammation)
and experimental set up (e.g., whole-body receptor KOs or
systemic receptor modulators) will complicate interpretation of
effects.
ADENOSINE RECEPTORS IN ADIPOSE
TISSUE
Adenosine accumulates extracellularly in response to
metabolic stress, tissue injury, hypoxia and inflammation
and concentrations can range from nanomolar to micromolar
in physiological and pathophysiological conditions, respectively
(Fredholm, 2014). Adenosine can bind to four different
G-protein-coupled receptors A1, A2A, A2B, and A3. A1R and
A2AR have high affinity for adenosine, while A2BR and A3R
have relatively lower affinity. A1R and A3R are coupled to Gi/o
proteins and their activation inhibits cAMP production and
decreases PKA activity. A2AR and A2BR are coupled to Gs/olf
proteins and stimulate cAMP production, thus activating PKA.
In addition, some adenosine receptors also activate PLC, Ca2+
signaling and mitogen-activated protein kinases (Fredholm et al.,
2011).
Adenosine has a key role in regulating many patho-
/physiological processes in AT and adipocytes (Figure 1). The
most studied adenosine receptor is the A1, identified in WAT
of many species (Trost and Schwabe, 1981; Larrouy et al., 1991;
Strong et al., 1993; Mersmann et al., 1997; Tatsis-Kotsidis and
Erlanger, 1999). Using pharmacological tools and whole body
A1R KO mice, it was shown that activation of this receptor
in rodents has anti-lipolytic effects mediated by inhibition of
cAMP production and decrease in PKA and lipase activities
(Fredholm, 1978; Schoelch et al., 2004; Dhalla et al., 2007a;
Johansson et al., 2008). Rat WA are more responsive than BA
to inhibition of lipolysis by the A1R stimulators PIA and NECA
(Saggerson and Jamal, 1990), probably due to higher expression
of the receptor in WA (Gnad et al., 2014). A1R activation also
increases lipogenesis in mouse and rat WA (Johansson et al.,
2008; Szkudelski et al., 2009). The A1R is also implicated in
adipogenesis (Gharibi et al., 2012) and leptin production in WA
(Cheng et al., 2000; Rice et al., 2000). All these A1R-mediated
effects highlight the importance of adenosine signaling in AT, and
predict impact on whole body metabolism. In accordance, A1R
KO mice have increased fat mass and body weight, and impaired
glucose tolerance and insulin sensitivity (Faulhaber-Walter et al.,
2011; Yang et al., 2015). In contrast, mice overexpressing the
A1R in AT are protected from obesity-induced insulin resistance
(Dong et al., 2001).
Another fairly well studied receptor is the A2BR, detected in
adipocytes and SVF (Gnad et al., 2014). In vitro experiments on
murine pre-osteoblast cell line expressing either human A2BR
or A1R showed that A1R stimulated adipogenesis, while the
A2BR inhibited both adipogenesis and lipogenesis, supporting
osteoblastogenesis pathways (Gharibi et al., 2012). In in vivo
experiments, A2BR expression seems to correlate with parameters
of obesity, both in rodents and humans, and the receptor is
upregulated in visceral AT of mice fed HFD (Johnston-Cox
et al., 2012). Genetic KO of the receptor is also associated
with metabolic disorders. Whole body A2BR KO led to AT
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FIGURE 1 | Effect of pharmacological and genetic modulation of adenosine receptors in white (left) and brown (right) adipocytes and in various mouse models. The
figure shows agonists (green), antagonists (red) and knockout animals (red) that have been used in the studies quoted in this review to address the function of the
specific receptor.
inflammation, insulin resistance, impaired glucose and lipid
metabolism in mice (Johnston-Cox et al., 2012; Csoka et al.,
2014; Peleli et al., 2015). Importantly, systemic administration
of the A2B specific agonist BAY 60-6583, following HFD regime,
lowered plasma glucose, insulin and IL-6 levels, and ameliorated
type-2 diabetes in mice (Johnston-Cox et al., 2012). These
animal studies and a recent study (Johnston-Cox et al., 2014)
are interpreted mainly in terms of the A2BR activation of
WAT macrophage. Nevertheless, involvement of adipocyte A2BR
cannot be excluded.
The A2AR may have a major role in BAT, where it is
more abundantly expressed compared to WAT (Gnad et al.,
2014). Early studies showed that adenosine inhibited lipolysis
in BA from rat or hamster, probably via A1R (Schimmel and
McCarthy, 1984; Woodward and Saggerson, 1986). In contrast,
recent work shows that adenosine and A2AR agonists (CGS21680
or PSB-0777) activated lipolysis in human and murine BA,
and to explain differences in the studies authors proposed
species-related differential receptor expression (Gnad et al.,
2014). Moreover, agonists used in this study increased energy
expenditure, induced browning of WAT, improved glucose
tolerance and protected C57Bl/6 mice from diet-induced obesity,
thus revealing a promising thermogenic effect of adenosine.
Similar effect on glucose homeostasis was reported for another
A2AR agonist CGS21680 administered to Swiss strain mice fed
with HFD (DeOliveira et al., 2017). No alteration in body weight
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or adiposity was detected, though decrease in some inflammatory
markers was observed. The difference in animal obesity detected
in the two studies could be due to different time regimes of drug
treatment (8 weeks vs. 2 weeks), differences in strains of mice
used (see below for comments on C57Bl/6 strain), or specificity
of different A2AR agonists used.
There are only a few studies on A3R in adipocytes/AT. Isolated
human WA express higher levels of A3R mRNA compared to BA.
But inhibition of the receptor with MRS1523 had no significant
effect on modulating lipolysis, at least in murine BA (Gnad
et al., 2014). However, the A3R KO mice had less abdominal
and total body fat, and mice were protected from hypertension
and cardiovascular diseases in the chronic kidney disease model
tested (Yang et al., 2016).
Taken together, there is strong evidence that adipocytes
express all types of adenosine receptors that regulate patho-
/physiological processes (Figure 1). There is a consensus that
A1R regulates lipolysis and therefore FFAs levels, which play
a significant role in the pathogenesis of insulin resistance,
diabetes, and cardiovascular diseases (Dhalla et al., 2009;
Antonioli et al., 2015). Several A1R agonists, e.g., SDZWAG994
(Ishikawa et al., 1998), ARA (Zannikos et al., 2001), and RPR749
(Shah et al., 2004), have been clinically evaluated as anti-
lipolytic agents for the treatment of hypertriglyceridemia and
type-2 diabetes. Though, development of full A1R agonists has
been limited by (i) the debilitating side effects induced by
the activation of the receptors in heart and kidney of animal
models (Belardinelli et al., 1989; Wu et al., 2001); and (ii) a
well-characterized desensitization of the receptor after repeated
exposure to full agonists (Hoffman et al., 1986; Dhalla et al.,
2007b). However, selective partial A1R agonists, e.g., CPA and
GS-9667 (CVT-3619), effectively lowered plasma FFA levels
without detectable cardiovascular side effects in rodents and
humans (Dhalla et al., 2007a,b). These effects were achieved by
administering lower concentrations of these drugs, which acted
predominantly on AT, as it has larger A1R reserve compared
to other tissues (i.e., atrioventricular node) (Staehr et al., 2013).
Furthermore, given the role of the A2BR in glucose and lipid
homeostasis, and AT inflammation, this receptor could be a
promising target for the treatment of metabolic diseases. Finally,
finding that activation of A2AR induces beiging of WA and
activates BA (Gnad et al., 2014) may stimulate development of
new pharmacological interventions for the treatment of obesity
and metabolic disease.
PURINERGIC P2 RECEPTORS IN
ADIPOSE TISSUE
In contrast to adenosine, patho-/physiological functions of ATP
and other nucleotides have not been studied so extensively in
AT. Tri- and di-nucleotides signal through P2R belonging to
two main families: the ionotropic P2XRs and the metabotropic
G-protein coupled P2YRs. The P2XRs (P2X1–7) are ligand-
gated cation channels activated primarily by ATP (North, 2016).
The P2YR subtypes can be stimulated by different endogenous
nucleotides and most potent ones (in humans) are given in
brackets. P2Y1R (ADP), P2Y2R (UTP), P2Y4R (UTP), P2Y6R
(UDP) receptors couple to Gq proteins and thus activate PLC-β,
mobilizing Ca2+ from intracellular stores. P2Y11R (ATP) couple
in addition to Gs proteins increase cAMP, while P2Y12R (ADP),
P2Y13R (ADP), and P2Y14R (UDP, UDP-glucose) couple to
Gi proteins and inhibit cAMP formation (von Kugelgen and
Hoffmann, 2016).
Early studies by Lee and Pappone (1997a,b) and Lee S.C. et al.
(2005) used patch-clamp, Ca2+ imaging and mRNA analysis to
fingerprint functional P2XRs and P2YRs in WA and BA. Here,
we will focus on role of P2Rs in regulating multiple adipocyte-
specific processes as summarized in Figure 2.
P2Rs regulate adipogenesis. Several studies used expression
profiling and functional assays to describe that P2Y1R, P2Y2R or
P2Y4R and P2Y11R positively affected adipogenic differentiation
of stem cells derived from bone marrow or AT (Kawano et al.,
2006; Zippel et al., 2012; Ciciarello et al., 2013; Li et al.,
2016). In contrast, P2Y4R activation (UTP, MRS4062) inhibited
cardiac AT-derived stem cells differentiation and P2Y4R KO
mice developed bigger cardiac AT mass and higher expression
of UCP1 (Lemaire et al., 2017). The opposite effect of P2Y4R in
the mentioned studies could be related to the higher receptor
expression in cardiac AT compared to other fat depots and/or
beige/BA lineage in the cardiac tissue. Three other receptors
have anti-adipogenic effects – P2Y13, P2Y14, and P2X7 (Zippel
et al., 2012; Biver et al., 2013). Interestingly, P2X7R KO male
mice had increased body weight, adipocyte hyperplasia in fat
pads, and ectopic lipid accumulation in kidney, salivary glands,
and pancreas (Beaucage et al., 2014). Other in vitro and in vivo
studies indicate that the P2X7R stimulation directs differentiation
of MSCs toward the osteoblast lineage rather than toward
adipocytes (Li et al., 2015).
P2Rs are also implicated in lipid metabolism. One study on
isolated rat WA shows that ATP, UTP, and BzATP, probably by
activating different P2Rs, had dual effects – activated lipolysis
and inhibited insulin-induced leptin production (Lee H. et al.,
2005). In contrast, no lipolytic effect of ATP was found in a
similar cellular model (Schodel et al., 2004). The explanation
for these divergent results could be that the two studies used
different ATP concentrations, thus affecting different palette of
P2Rs. Furthermore, in the latter study on isolated WA, ATP
stimulated lipogenesis but had no effect on glucose transport
(Schodel et al., 2004).
The role of purinergic signaling in glucose uptake in
adipocytes has been investigated in 1980s. Two studies showed
that low concentrations of ATP inhibited insulin-stimulated
glucose transport in rat fat cells (Chang and Cuatrecasas, 1974;
Halperin et al., 1978), and it was assumed that extracellular ATP
had direct inhibitory effect on the insulin receptor. More recently,
it was shown that P2Y6R activation by UDP or MRS2957
increased GLUT-4 translocation and glucose uptake in primary
WA and 3T3-L1 cells (Balasubramanian et al., 2014).
In addition to effects on adipogenesis, lipid metabolism, and
glucose transport, P2Rs affect leptin and adiponectin production
and secretion, but activation of different P2R subtypes might lead
to opposite effects. ATP and BzATP reduced leptin mRNA levels
and inhibited insulin-induced leptin secretion in rat WA (Lee H.
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FIGURE 2 | Effect of pharmacological and genetic modulation of P2X and P2Y receptors in white (left) and brown (right) adipocytes and in various mouse models.
The figure lists agonists (green), antagonists (red) and knockout animals (red) that have been used in the studies quoted in this review to address the function of the
specific receptor.
et al., 2005). In another study, inhibition of P2Y1R by MRS2500
decreased leptin production under basal and insulin-stimulated
conditions in isolated mouse WA (Laplante et al., 2010).
Furthermore, the study showed that plasma leptin was lower in
mice lacking P2Y1R, however, in mice on HFD the plasma leptin
was enhanced and the inhibitory effect of receptor KO was not
observed. Stimulation of P2Y4R by UTP or MRS4062 inhibited
adiponectin expression and secrection in cardiac adipocytes and
P2Y4R KO mice showed increased adiponectin secrection in
hypoxia and a cardioprotective phenotype (Lemaire et al., 2017).
Adenosine triphosphate is generally considered as an
inflammatory molecule (Idzko et al., 2014). Particularly the
P2X7R mediates inflammation in AT. In primary adipocytes from
rat epididymal fat, millimolar concentrations of ATP evoked
inflammatory response and led to impaired insulin signaling and
glucose uptake (Yu and Jin, 2010). Visceral and subcutaneous
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human AT express functional P2X7R, which could be involved
in release of inflammatory cytokines such as IL-6, TNFα, and
PAI-1 (Madec et al., 2011). Interestingly, this study showed that
P2X7R expression appeared to be high in adipocytes isolated
from subjects affected by metabolic syndrome. The P2X7R
and NLRP3 inflammasome expression and IL-1β secretion
was elevated in metabolically unhealthy obese individuals and
the receptor expression correlated with body mass index and
metabolic syndrome scores (Pandolfi et al., 2015). Whether this
was due to effects on adipocytes or infiltrating immune cells
is not clear (Pandolfi et al., 2016). In contrast, an earlier study
concluded that the P2X7R was not involved in obesity-associated
inflammasome activation. This was based on the observation that
P2X7R KO mice on the C57BL/6 background and fed on HFD
were not protected from obesity, AT inflammation and associated
metabolic abnormalities (Sun et al., 2012). The C57BL/6 mice
though have a single nucleotide polymorphism in the P2X7R that
compromises the immune response (Rissiek et al., 2015), which
could explain discrepancies in inflammasome activation in the
two studies.
Rodent BA, express several P2X and P2Y receptors and
stimulation with ATP leads to exocytosis and heat production
(Lee and Pappone, 1997a; Lee S.C. et al., 2005). In a more
recent study, ATPγS, enhanced UCP1 expression and induced
browning in BAT in conditions of low adaptive thermogenesis
and b-adrenergic receptor KO mice (Razzoli et al., 2016). This
effect is most likely exerted via more than one receptor and
P2X5R, P2X7R, and P2Y12R are overexpressed in β-less BAT.
Interestingly, P2X5R is proposed as a novel cell surface marker
for beige and BA as its mRNA levels are markedly higher in
mouse BAT compared to WAT and other tissues (Ussar et al.,
2014). Furthermore, the P2X5R expression increased in both BAT
and subcutaneous WAT upon chronic cold exposure, paralleling
expression of UCP1 (Ussar et al., 2014; Garcia et al., 2016; Razzoli
et al., 2016). However, mechanisms of P2X5R mediated effects in
AT are unknown.
Taken together, there is good evidence that P2Rs affect a wide
range of patho-/physiological processes in rodent and human
AT. Many of these processes, e.g., lipid deposition, metabolism,
endocrine activity, and inflammation, are deregulated during
pathological states such as obesity and diabetes. However, P2Rs
modulators have not yet been tested in clinical trials for treatment
of metabolic disorders. Future research is still needed to dissect
functions of P2R subtypes in adipocytes and AT before best P2R
targets and drugs are selected.
CONCLUSION AND PERSPECTIVES
In this review, we discussed contribution of P1 and P2 receptors
to modulation of AT functions and considered processes
that may underlie their role in metabolic disorders. Several
preclinical studies indicate that pharmacological manipulation
of purinergic signaling in adipocytes and AT has interesting
potential for treating metabolic disorders. However, translation
of these findings into clinical trials will require more detailed
knowledge about the role of extracellular ATP and adenosine
in the onset and progression of obesity-related disorders,
as well as about the basic physiology and pharmacology of
purinergic receptors expressed in adipocytes and in AT. In
this context, it will be necessary to: (i) know differential
expression of adenosine and P2Rs in white, brown and beige
adipocytes belonging to different fat depots (subcutaneous,
visceral, cardiac etc.); (ii) clarify sources and concentrations of
nucleotides/sides and modifying enzymes present in specific AT
microenvironments; (iii) understand role of purinergic system
in interplay between different cells in AT microenvironment
and potential patho-/physiological conditions which may affect
those.
AUTHOR CONTRIBUTIONS
MT wrote the draft and prepared figures. IN contributed to
planning and writing of the review.
FUNDING
Work in our laboratory that inspired this review was funded
by the Independent Research Fund Denmark/Natural Sciences
(4002-00162B).
REFERENCES
Adamson, S. E., Meher, A. K., Chiu, Y. H., Sandilos, J. K., Oberholtzer, N. P.,
Walker, N. N., et al. (2015). Pannexin 1 is required for full activation of insulin-
stimulated glucose uptake in adipocytes. Mol. Metab. 4, 610–618. doi: 10.1016/
j.molmet.2015.06.009
Antonioli, L., Blandizzi, C., Csoka, B., Pacher, P., and Hasko, G. (2015). Adenosine
signalling in diabetes mellitus–pathophysiology and therapeutic considerations.
Nat. Rev. Endocrinol. 11, 228–241. doi: 10.1038/nrendo.2015.10
Antonioli, L., Fornai, M., Colucci, R., Ghisu, N., Tuccori, M., Del, T. M., et al.
(2008). Regulation of enteric functions by adenosine: pathophysiological and
pharmacological implications. Pharmacol. Ther. 120, 233–253. doi: 10.1016/j.
pharmthera.2008.08.010
Balasubramanian, R., Robaye, B., Boeynaems, J. M., and Jacobson, K. A. (2014).
Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes
by P2Y6 receptor agonists. PLOS ONE 9:e116203. doi: 10.1371/journal.pone.
0116203
Beaucage, K. L., Xiao, A., Pollmann, S. I., Grol, M. W., Beach, R. J., Holdsworth,
D. W., et al. (2014). Loss of P2X7 nucleotide receptor function leads to abnormal
fat distribution in mice. Purinergic Signal. 10, 291–304. doi: 10.1007/s11302-
013-9388-x
Belardinelli, L., Linden, J., and Berne, R. M. (1989). The cardiac effects of adenosine.
Prog. Cardiovasc. Dis. 32, 73–97. doi: 10.1016/0033-0620(89)90015-7
Biver, G., Wang, N., Gartland, A., Orriss, I., Arnett, T. R., Boeynaems, J. M.,
et al. (2013). Role of the P2Y13 receptor in the differentiation of bone
marrow stromal cells into osteoblasts and adipocytes. Stem Cells 31, 2747–2758.
doi: 10.1002/stem.1411
Bulloch, J. M., and Daly, C. J. (2014). Autonomic nerves and perivascular
fat: interactive mechanisms. Pharmacol. Ther. 143, 61–73. doi: 10.1016/j.
pharmthera.2014.02.005
Burnstock, G. (2007). Physiology and pathophysiology of purinergic
neurotransmission. Physiol. Rev. 87, 659–797. doi: 10.1152/physrev.00043.2006
Burnstock, G. (2013). Purinergic signalling: pathophysiology and therapeutic
potential. Keio J. Med. 62, 63–73. doi: 10.2302/kjm.2013-0003-RE
Frontiers in Pharmacology | www.frontiersin.org 6 November 2017 | Volume 8 | Article 878
fphar-08-00878 November 22, 2017 Time: 14:56 # 7
Tozzi and Novak Purinergic Receptors in Adipose Tissue
Burnstock, G., and Novak, I. (2013). Purinergic signalling and diabetes. Purinergic
Signal. 9, 307–324. doi: 10.1007/s11302-013-9359-2
Chang, K. J., and Cuatrecasas, P. (1974). Adenosine triphosphate-dependent
inhibition of insulin-stimulated glucose transport in fat cells. Possible role of
membrane phosphorylation. J. Biol. Chem. 249, 3170–3180.
Chen, J. F., Eltzschig, H. K., and Fredholm, B. B. (2013). Adenosine receptors
as drug targets–what are the challenges? Nat. Rev. Drug Discov. 12, 265–286.
doi: 10.1038/nrd3955
Cheng, J. T., Liu, I. M., Chi, T. C., Shinozuka, K., Lu, F. H., Wu, T. J., et al. (2000).
Role of adenosine in insulin-stimulated release of leptin from isolated white
adipocytes of Wistar rats. Diabetes Metab. Res. Rev. 49, 20–24. doi: 10.2337/
diabetes.49.1.20
Ciciarello, M., Zini, R., Rossi, L., Salvestrini, V., Ferrari, D., Manfredini, R.,
et al. (2013). Extracellular purines promote the differentiation of human
bone marrow-derived mesenchymal stem cells to the osteogenic and
adipogenic lineages. Stem Cells Dev. 22, 1097–1111. doi: 10.1089/scd.2012.
0432
Corriden, R., and Insel, P. A. (2010). Basal release of ATP: an autocrine-paracrine
mechanism for cell regulation. Sci. Signal. 3:re1. doi: 10.1126/scisignal.3104re1
Csoka, B., Koscso, B., Toro, G., Kokai, E., Virag, L., Nemeth, Z. H., et al. (2014).
A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue
inflammation via maintaining alternative macrophage activation. Diabetes
Metab. Res. Rev. 63, 850–866. doi: 10.2337/db13-0573
DeOliveira, C. C., Paiva Caria, C. R., Ferreira Gotardo, E. M., Ribeiro, M. L.,
and Gambero, A. (2017). Role of A1 and A2A adenosine receptor agonists in
adipose tissue inflammation induced by obesity in mice. Eur. J. Pharmacol. 799,
154–159. doi: 10.1016/j.ejphar.2017.02.017
Dhalla, A. K., Chisholm, J. W., Reaven, G. M., and Belardinelli, L. (2009). A1
adenosine receptor: role in diabetes and obesity. Handb. Exp. Pharmacol. 193,
271–295. doi: 10.1007/978-3-540-89615-9_9
Dhalla, A. K., Santikul, M., Smith, M., Wong, M. Y., Shryock, J. C., and
Belardinelli, L. (2007a). Antilipolytic activity of a novel partial A1 adenosine
receptor agonist devoid of cardiovascular effects: comparison with nicotinic
acid. J. Pharmacol. Exp. Ther. 321, 327–333.
Dhalla, A. K., Wong, M. Y., Voshol, P. J., Belardinelli, L., and Reaven, G. M.
(2007b). A1 adenosine receptor partial agonist lowers plasma FFA and improves
insulin resistance induced by high-fat diet in rodents. Am. J. Physiol. Endocrinol.
Metab. 292, E1358–E1363.
Dong, Q., Ginsberg, H. N., and Erlanger, B. F. (2001). Overexpression of the A1
adenosine receptor in adipose tissue protects mice from obesity-related insulin
resistance. Diabetes Obes. Metab. 3, 360–366. doi: 10.1046/j.1463-1326.2001.
00158.x
Faulhaber-Walter, R., Jou, W., Mizel, D., Li, L., Zhang, J., Kim, S. M.,
et al. (2011). Impaired glucose tolerance in the absence of adenosine A1
receptor signaling. Diabetes Metab. Res. Rev. 60, 2578–2587. doi: 10.2337/db
11-0058
Fredholm, B. B. (1978). Effect of adenosine, adenosine analogues and drugs
inhibiting adenosine inactivation on lipolysis in rat fat cells. Acta Physiol. Scand.
102, 191–198. doi: 10.1111/j.1748-1716.1978.tb06062.x
Fredholm, B. B. (2014). Adenosine–a physiological or pathophysiological agent?
J. Mol. Med. (Berl) 92, 201–206. doi: 10.1007/s00109-013-1101-6
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., and Muller,
C. E. (2011). International union of basic and clinical pharmacology. LXXXI.
Nomenclature and classification of adenosine receptors–an update. Pharmacol.
Rev. 63, 1–34. doi: 10.1124/pr.110.003285
Garcia, R. A., Roemmich, J. N., and Claycombe, K. J. (2016). Evaluation of markers
of beige adipocytes in white adipose tissue of the mouse. Nutr. Metab. (Lond).
13:24. doi: 10.1186/s12986-016-0081-2
Gharibi, B., Abraham, A. A., Ham, J., and Evans, B. A. (2012). Contrasting effects
of A1 and A2b adenosine receptors on adipogenesis. Int. J. Obes. (Lond). 36,
397–406. doi: 10.1038/ijo.2011.129
Gnad, T., Scheibler, S., von, K. I, Scheele, C., Kilic, A., Glode, A., et al. (2014).
Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A
receptors. Nature 516, 395–399. doi: 10.1038/nature13816
Guilherme, A., Virbasius, J. V., Puri, V., and Czech, M. P. (2008). Adipocyte
dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev.
Mol. Cell Biol. 9, 367–377. doi: 10.1038/nrm2391
Halperin, M. L., Mak, M. L., and Taylor, W. M. (1978). Control of glucose transport
in adipose tissue of the rat: role of insulin, ATP, and intracellular metabolites.
Can. J. Biochem. 56, 708–712. doi: 10.1139/o78-106
Harms, M., and Seale, P. (2013). Brown and beige fat: development, function and
therapeutic potential. Nat. Med. 19, 1252–1263. doi: 10.1038/nm.3361
Hoffman, B. B., Chang, H., Dall’Aglio, E., and Reaven, G. M. (1986).
Desensitization of adenosine receptor-mediated inhibition of lipolysis.
The mechanism involves the development of enhanced cyclic adenosine
monophosphate accumulation in tolerant adipocytes. J. Clin. Invest. 78,
185–190. doi: 10.1172/JCI112550
Idzko, M., Ferrari, D., and Eltzschig, H. K. (2014). Nucleotide signalling during
inflammation. Nature 509, 310–317. doi: 10.1038/nature13085
Ishikawa, J., Mitani, H., Bandoh, T., Kimura, M., Totsuka, T., and Hayashi, S.
(1998). Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-O-methyl-
adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive
rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. 39, 3–9.
doi: 10.1016/S0168-8227(97)00116-2
Jacobson, K. A., and Muller, C. E. (2016). Medicinal chemistry of adenosine, P2Y
and P2X receptors. Neuropharmacology 104, 31–49. doi: 10.1016/j.neuropharm.
2015.12.001
Johansson, S. M., Lindgren, E., Yang, J. N., Herling, A. W., and Fredholm,
B. B. (2008). Adenosine A1 receptors regulate lipolysis and lipogenesis in
mouse adipose tissue-interactions with insulin. Eur. J. Pharmacol. 597, 92–101.
doi: 10.1016/j.ejphar.2008.08.022
Johnston-Cox, H., Eisenstein, A. S., Koupenova, M., Carroll, S., and Ravid, K.
(2014). The macrophage A2B adenosine receptor regulates tissue insulin
sensitivity. PLOS ONE 9:e98775. doi: 10.1371/journal.pone.0098775
Johnston-Cox, H., Koupenova, M., Yang, D., Corkey, B., Gokce, N., Farb, M. G.,
et al. (2012). The A2b adenosine receptor modulates glucose homeostasis and
obesity. PLOS ONE 7:e40584. doi: 10.1371/journal.pone.0040584
Junger, W. G. (2011). Immune cell regulation by autocrine purinergic signalling.
Nat. Rev. Immunol. 11, 201–212. doi: 10.1038/nri2938
Kawano, S., Otsu, K., Kuruma, A., Shoji, S., Yanagida, E., Muto, Y., et al.
(2006). ATP autocrine/paracrine signaling induces calcium oscillations and
NFAT activation in human mesenchymal stem cells. Cell Calcium 39, 313–324.
doi: 10.1016/j.ceca.2005.11.008
Kim, S. H., and Plutzky, J. (2016). Brown fat and browning for the treatment
of obesity and related metabolic disorders. Diabetes Metab. J. 40, 12–21.
doi: 10.4093/dmj.2016.40.1.12
Kusminski, C. M., Bickel, P. E., and Scherer, P. E. (2016). Targeting adipose tissue in
the treatment of obesity-associated diabetes. Nat. Rev. Drug Discov. 15, 639–660.
doi: 10.1038/nrd.2016.75
Laplante, M. A., Monassier, L., Freund, M., Bousquet, P., and Gachet, C. (2010).
The purinergic P2Y1 receptor supports leptin secretion in adipose tissue.
Endocrinology 151, 2060–2070. doi: 10.1210/en.2009-1134
Larrouy, D., Galitzky, J., and Lafontan, M. (1991). A1 adenosine receptors in the
human fat cell: tissue distribution and regulation of radioligand binding. Eur. J.
Pharmacol. 206, 139–147. doi: 10.1016/0922-4106(91)90022-A
Lazarowski, E. R. (2012). Vesicular and conductive mechanisms of nucleotide
release. Purinergic Signal. 8, 359–373. doi: 10.1007/s11302-012-9304-9
Lee, H., Jun, D. J., Suh, B. C., Choi, B. H., Lee, J. H., Do, M. S., et al. (2005). Dual
roles of P2 purinergic receptors in insulin-stimulated leptin production and
lipolysis in differentiated rat white adipocytes. J. Biol. Chem. 280, 28556–28563.
doi: 10.1074/jbc.M411253200
Lee, S. C., Vielhauer, N. S., Leaver, E. V., and Pappone, P. A. (2005). Differential
regulation of ca(2+) signaling and membrane trafficking by multiple p2
receptors in brown adipocytes. J. Membr. Biol. 207, 131–142. doi: 10.1007/
s00232-005-0808-x
Lee, S. C., and Pappone, P. A. (1997a). Effects of P2 purinergic receptor stimulation
in brown adipocytes. Am. J. Physiol. 273(2 Pt 1), C679–C686.
Lee, S. C., and Pappone, P. A. (1997b). Membrane responses to extracellular ATP
in rat isolated white adipocytes. Pflugers Arch. 434, 422–428. doi: 10.1007/
s004240050416
Lemaire, A., Vanorle, M., Horckmans, M., di Pietrantonio, L., Clouet, S., Robaye, B.,
et al. (2017). Mouse P2Y4 nucleotide receptor is a negative regulator of cardiac
adipose-derived stem cell differentiation and cardiac fat formation. Stem Cells
Dev. 26, 363–373. doi: 10.1089/scd.2016.0166
Frontiers in Pharmacology | www.frontiersin.org 7 November 2017 | Volume 8 | Article 878
fphar-08-00878 November 22, 2017 Time: 14:56 # 8
Tozzi and Novak Purinergic Receptors in Adipose Tissue
Li, W., Li, G., Zhang, Y., Wei, S., Song, M., Wang, W., et al. (2015). Role of P2 x
7 receptor in the differentiation of bone marrow stromal cells into osteoblasts
and adipocytes. Exp. Cell Res. 339, 367–379. doi: 10.1016/j.yexcr.2015.10.011
Li, W., Wei, S., Liu, C., Song, M., Wu, H., and Yang, Y. (2016). Regulation of the
osteogenic and adipogenic differentiation of bone marrow-derived stromal cells
by extracellular uridine triphosphate: the role of P2Y2 receptor and ERK1/2
signaling. Int. J. Mol. Med. 37, 63–73. doi: 10.3892/ijmm.2015.2400
Madec, S., Rossi, C., Chiarugi, M., Santini, E., Salvati, A., Ferrannini, E.,
et al. (2011). Adipocyte P2X7 receptors expression: a role in modulating
inflammatory response in subjects with metabolic syndrome? Atherosclerosis
219, 552–558. doi: 10.1016/j.atherosclerosis.2011.09.012
Mersmann, H. J., Carey, G. B., and Smith, E. O. (1997). Adipose tissue beta-
adrenergic and A1 adenosine receptors in suckling pigs. J. Anim. Sci. 75,
3161–3168. doi: 10.2527/1997.75123161x
North, R. A. (2016). P2X receptors. Philos. Trans. R. Soc. Lond. B Biol. Sci.
371:20150427. doi: 10.1098/rstb.2015.0427
Novak, I. (2011). Purinergic signalling in epithelial ion transport: regulation of
secretion and absorption. Acta Physiol. (Oxf). 202, 501–522. doi: 10.1111/j.
1748-1716.2010.02225.x
Pandolfi, J., Ferraro, A., Lerner, M., Serrano, J. R., Dueck, A., Fainboim, L., et al.
(2015). Purinergic signaling modulates human visceral adipose inflammatory
responses: implications in metabolically unhealthy obesity. J. Leukoc. Biol. 97,
941–949. doi: 10.1189/jlb.3A1214-626R
Pandolfi, J. B., Ferraro, A. A., Sananez, I., Gancedo, M. C., Baz, P., Billordo, L. A.,
et al. (2016). ATP-induced inflammation drives tissue-resident Th17 cells in
metabolically unhealthy obesity. J. Immunol. 196, 3287–3296. doi: 10.4049/
jimmunol.1502506
Peleli, M., and Carlstrom, M. (2017). Adenosine signaling in diabetes mellitus and
associated cardiovascular and renal complications. Mol. Aspects Med. 55, 62–74.
doi: 10.1016/j.mam.2016.12.001
Peleli, M., Hezel, M., Zollbrecht, C., Persson, A. E., Lundberg, J. O., Weitzberg, E.,
et al. (2015). In adenosine A2B knockouts acute treatment with inorganic
nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the
liver. Front. Physiol. 6:222. doi: 10.3389/fphys.2015.00222
Rancoule, C., Dusaulcy, R., Treguer, K., Gres, S., Attane, C., and Saulnier-Blache,
J. S. (2014). Involvement of autotaxin/lysophosphatidic acid signaling in obesity
and impaired glucose homeostasis. Biochimie 96, 140–143. doi: 10.1016/j.biochi.
2013.04.010
Razzoli, M., Frontini, A., Gurney, A., Mondini, E., Cubuk, C., Katz, L. S., et al.
(2016). Stress-induced activation of brown adipose tissue prevents obesity in
conditions of low adaptive thermogenesis. Mol. Metab. 5, 19–33. doi: 10.1016/j.
molmet.2015.10.005
Rice, A. M., Fain, J. N., and Rivkees, S. A. (2000). A1 adenosine receptor
activation increases adipocyte leptin secretion. Endocrinology 141, 1442–1445.
doi: 10.1210/endo.141.4.7423
Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F., and Adriouch, S. (2015). P2X7
on mouse T cells: one channel, many functions. Front. Immunol. 6:204.
doi: 10.3389/fimmu.2015.00204
Saggerson, E. D., and Jamal, Z. (1990). Differences in the properties of A1-type
adenosine receptors in rat white and brown adipocytes. Biochem. J. 269,
157–161. doi: 10.1042/bj2690157
Schimmel, R. J., and McCarthy, L. (1984). Role of adenosine as an endogenous
regulator of respiration in hamster brown adipocytes. Am. J. Physiol.
246(3 Pt 1), C301–C307.
Schodel, J., Weise, I., Klinger, R., and Schmidt, M. (2004). Stimulation of
lipogenesis in rat adipocytes by ATP, a ligand for P2-receptors. Biochem.
Biophys. Res. Commun. 321, 767–773. doi: 10.1016/j.bbrc.2004.06.179
Schoelch, C., Kuhlmann, J., Gossel, M., Mueller, G., Neumann-Haefelin, C.,
Belz, U., et al. (2004). Characterization of adenosine-A1 receptor-mediated
antilipolysis in rats by tissue microdialysis, 1H-spectroscopy, and glucose clamp
studies. Diabetes Metab. Res. Rev. 53, 1920–1926. doi: 10.2337/diabetes.53.7.
1920
Shah, B., Rohatagi, S., Natarajan, C., Kirkesseli, S., Baybutt, R., and Jensen, B. K.
(2004). Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering
adenosine A1 agonist, RPR749, in healthy subjects. Am. J. Ther. 11, 175–189.
doi: 10.1097/00045391-200405000-00005
Staehr, P. M., Dhalla, A. K., Zack, J., Wang, X., Ho, Y. L., Bingham, J., et al. (2013).
Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667,
an A(1) adenosine receptor partial agonist. J. Clin. Pharmacol. 53, 385–392.
doi: 10.1002/jcph.9
Strong, P., Anderson, R., Coates, J., Ellis, F., Evans, B., Gurden, M. F., et al. (1993).
Suppression of non-esterified fatty acids and triacylglycerol in experimental
animals by the adenosine analogue GR79236. Clin. Sci. (Lond). 84, 663–669.
doi: 10.1042/cs0840663
Sun, S., Xia, S., Ji, Y., Kersten, S., and Qi, L. (2012). The ATP-P2X7 signaling axis
is dispensable for obesity-associated inflammasome activation in adipose tissue.
Diabetes Metab. Res. Rev. 61, 1471–1478. doi: 10.2337/db11-1389
Szkudelski, T., Szkudelska, K., and Nogowski, L. (2009). Effects of adenosine A1
receptor antagonism on lipogenesis and lipolysis in isolated rat adipocytes.
Physiol. Res. 58, 863–871.
Tatsis-Kotsidis, I., and Erlanger, B. F. (1999). A1 adenosine receptor of human
and mouse adipose tissues: cloning, expression, and characterization. Biochem.
Pharmacol. 58, 1269–1277. doi: 10.1016/S0006-2952(99)00214-2
Trost, T., and Schwabe, U. (1981). Adenosine receptors in fat cells. Identification by
(–)-N6-[3H]phenylisopropyladenosine binding. Mol. Pharmacol. 19, 228–235.
Ussar, S., Lee, K. Y., Dankel, S. N., Boucher, J., Haering, M. F., Kleinridders, A.,
et al. (2014). ASC-1, PAT2, and P2RX5 are cell surface markers for white, beige,
and brown adipocytes. Sci. Transl. Med. 6:247ra103. doi: 10.1126/scitranslmed.
3008490
von Kugelgen, I., and Hoffmann, K. (2016). Pharmacology and structure of P2Y
receptors. Neuropharmacology 104, 50–61. doi: 10.1016/j.neuropharm.2015.
10.030
Woodward, J. A., and Saggerson, E. D. (1986). Effect of adenosine deaminase,
N6-phenylisopropyladenosine and hypothyroidism on the responsiveness of
rat brown adipocytes to noradrenaline. Biochem. J. 238, 395–403. doi: 10.1042/
bj2380395
Wu, L., Belardinelli, L., Zablocki, J. A., Palle, V., and Shryock, J. C. (2001). A partial
agonist of the A(1)-adenosine receptor selectively slows AV conduction in
guinea pig hearts. Am. J. Physiol. Heart Circ. Physiol. 280, H334–H343.
Yang, T., Gao, X., Sandberg, M., Zollbrecht, C., Zhang, X. M., Hezel, M.,
et al. (2015). Abrogation of adenosine A1 receptor signalling improves
metabolic regulation in mice by modulating oxidative stress and
inflammatory responses. Diabetologia 58, 1610–1620. doi: 10.1007/s00125-015-
3570-3
Yang, T., Zollbrecht, C., Winerdal, M. E., Zhuge, Z., Zhang, X. M., Terrando, N.,
et al. (2016). Genetic abrogation of adenosine A3 receptor prevents
uninephrectomy and high salt-induced hypertension. J. Am. Heart Assoc.
5:e003868. doi: 10.1161/JAHA.116.003868
Yu, Z., and Jin, T. (2010). Extracellular high dosages of adenosine triphosphate
induce inflammatory response and insulin resistance in rat adipocytes. Biochem.
Biophys. Res. Commun. 402, 455–460. doi: 10.1016/j.bbrc.2010.10.028
Zannikos, P. N., Rohatagi, S., and Jensen, B. K. (2001). Pharmacokinetic-
pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor
agonist in healthy volunteers. J. Clin. Pharmacol. 41, 61–69. doi: 10.1177/
00912700122009845
Zimmermann, H., Zebisch, M., and Strater, N. (2012). Cellular function and
molecular structure of ecto-nucleotidases. Purinergic Signal. 8, 437–502.
doi: 10.1007/s11302-012-9309-4
Zippel, N., Limbach, C. A., Ratajski, N., Urban, C., Luparello, C., Pansky, A.,
et al. (2012). Purinergic receptors influence the differentiation of human
mesenchymal stem cells. Stem Cells Dev. 21, 884–900. doi: 10.1089/scd.2010.
0576
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer GY declared a past co-authorship with one of the authors IN to the
handling Editor.
Copyright © 2017 Tozzi and Novak. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 8 November 2017 | Volume 8 | Article 878
